Long-Term Impact of Ivacaftor on Healthcare Resource Utilization Among People with Cystic Fibrosis in the United States

INTRODUCTION: Ivacaftor was first approved in 2012 for the treatment of a select population of individuals with cystic fibrosis (CF), a rare, life-shortening genetic disease. Reductions in healthcare resource utilization (HCRU) associated with ivacaftor have been observed during limited follow-up an...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Argitaratua izan da:Pulm Ther
Egile Nagusiak: Thorat, Teja, McGarry, Lisa J., Jariwala-Parikh, Krutika, Limone, Brendan, Bonafede, Machaon, Chandarana, Keval, Konstan, Michael W.
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: Springer Healthcare 2021
Gaiak:
Brief Report
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC8137794/
https://ncbi.nlm.nih.gov/pubmed/33913076
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s41030-021-00154-9
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak